Search Results - "Namiki Izumi"

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial by Kudo, Masatoshi, Ueshima, Kazuomi, Ikeda, Masafumi, Torimura, Takuji, Tanabe, Nobukazu, Aikata, Hiroshi, Izumi, Namiki, Yamasaki, Takahiro, Nojiri, Shunsuke, Hino, Keisuke, Tsumura, Hidetaka, Kuzuya, Teiji, Isoda, Norio, Yasui, Kohichiroh, Aino, Hajime, Ido, Akio, Kawabe, Naoto, Nakao, Kazuhiko, Wada, Yoshiyuki, Yokosuka, Osamu, Yoshimura, Kenichi, Okusaka, Takuji, Furuse, Junji, Kokudo, Norihiro, Okita, Kiwamu, Johnson, Philip James, Arai, Yasuaki

“…This trial compared the efficacy and safety of transarterial chemoembolisation (TACE) plus sorafenib with TACE alone using a newly established TACE-specific…”
Get more information

Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update by Kokudo, Norihiro, Takemura, Nobuyuki, Hasegawa, Kiyoshi, Takayama, Tadatoshi, Kubo, Shoji, Shimada, Mitsuo, Nagano, Hiroaki, Hatano, Etsuro, Izumi, Namiki, Kaneko, Shuichi, Kudo, Masatoshi, Iijima, Hiroko, Genda, Takuya, Tateishi, Ryosuke, Torimura, Takuji, Igaki, Hiroshi, Kobayashi, Satoshi, Sakurai, Hideyuki, Murakami, Takamichi, Watadani, Takeyuki, Matsuyama, Yutaka

“…The fourth version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of…”
Get full text

Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey by Kokudo, Takashi, Hasegawa, Kiyoshi, Matsuyama, Yutaka, Takayama, Tadatoshi, Izumi, Namiki, Kadoya, Masumi, Kudo, Masatoshi, Kubo, Shoji, Sakamoto, Michiie, Nakashima, Osamu, Kumada, Takashi, Kokudo, Norihiro

“…Because of the rarity of hepatic vein tumor thrombus (HVTT) compared with portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma, little…”
Get full text

Letter: association of laboratory indexes and magnetic resonance elastography‐associated liver stiffness with complications and mortality—authors' reply by Tamaki, Nobuharu, Higuchi, Mayu, Kurosaki, Masayuki, Izumi, Namiki

“…LINKED CONTENT This article is linked to Higuchi et al papers. To view these articles, visit https://doi.org/10.1111/apt.16745 and…”
Get full text

Letter: predictive role of magnetic resonance elastography in chronic liver disease—still a long way to go. Authors' reply by Tamaki, Nobuharu, Higuchi, Mayu, Kurosaki, Masayuki, Izumi, Namiki

“…LINKED CONTENT This article is linked to Higuchi et al papers. To view these articles, visit https://doi.org/10.1111/apt.16745 and…”
Get full text

Diagnostic and treatment algorithm of the Japanese society of hepatology: a consensus-based practice guideline by Izumi, Namiki

“…In Japan, more than 70% of hepatocellular carcinomas (HCC) develop from hepatitis C virus infections and 15% are derived from hepatitis B infections. Since…”
Get more information

Report of the 20th Nationwide follow‐up survey of primary liver cancer in Japan by Kudo, Masatoshi, Izumi, Namiki, Kubo, Shoji, Kokudo, Norihiro, Sakamoto, Michiie, Shiina, Shuichiro, Tateishi, Ryosuke, Nakashima, Osamu, Murakami, Takamichi, Matsuyama, Yutaka, Takahashi, Arata, Miyata, Hiroaki, Takayama, Tadatoshi

“…In the 20th Nationwide Follow‐up Survey of Primary Liver Cancer in Japan, data from 21 075 new patients and 40 769 previously followed patients were compiled…”
Get full text

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset by Yamashita, Tatsuya, Kudo, Masatoshi, Ikeda, Kenji, Izumi, Namiki, Tateishi, Ryosuke, Ikeda, Masafumi, Aikata, Hiroshi, Kawaguchi, Yasunori, Wada, Yoshiyuki, Numata, Kazushi, Inaba, Yoshitaka, Kuromatsu, Ryoko, Kobayashi, Masahiro, Okusaka, Takuji, Tamai, Toshiyuki, Kitamura, Chifumi, Saito, Kenichi, Haruna, Katsuya, Okita, Kiwamu, Kumada, Hiromitsu

“…Background A phase 3, multinational, randomized, non-inferiority trial (REFLECT) compared the efficacy and safety of lenvatinib (LEN) and sorafenib (SOR) in…”
Get full text

A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation by Tateishi, Ryosuke, Seike, Masataka, Kudo, Masatoshi, Tamai, Hideyuki, Kawazoe, Seiji, Katsube, Takayuki, Ochiai, Toshimitsu, Fukuhara, Takahiro, Kano, Takeshi, Tanaka, Katsuaki, Kurokawa, Mineo, Yamamoto, Kazuhide, Osaki, Yukio, Izumi, Namiki, Imawari, Michio

“…Background Thrombocytopenia represents an obstacle for invasive procedures in chronic liver disease (CLD) patients. We aimed to estimate the appropriate dose…”
Get full text

Longitudinal association of magnetic resonance elastography‐associated liver stiffness with complications and mortality by Higuchi, Mayu, Tamaki, Nobuharu, Kurosaki, Masayuki, Inada, Kento, Kirino, Sakura, Yamashita, Koji, Hayakawa, Yuka, Osawa, Leona, Takaura, Kenta, Maeyashiki, Chiaki, Kaneko, Shun, Yasui, Yutaka, Takahashi, Yuka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Itakura, Jun, Loomba, Rohit, Enomoto, Nobuyuki, Izumi, Namiki

“…Summary Background Magnetic resonance elastography (MRE) has the highest diagnostic accuracy for liver fibrosis; however, the association between…”
Get full text

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan by Kobayashi, Masahiro, Kudo, Masatoshi, Izumi, Namiki, Kaneko, Shuichi, Azuma, Mie, Copher, Ronda, Meier, Genevieve, Pan, Janice, Ishii, Mika, Ikeda, Shunya

“…Background Lenvatinib demonstrated a treatment effect on overall survival by the statistical confirmation of non-inferiority to sorafenib for the first-line…”
Get full text

Reply to Wang et al by Kirino, Sakura, Tamaki, Nobuharu, Kurosaki, Masayuki, Izumi, Namiki

Get full text

Recent advances of radiofrequency ablation for early hepatocellular carcinoma by Izumi, Namiki

“…Hepatocellular carcinoma (HCC) is the third leading cause of death in the malignant neoplastic diseases in the world. Surgical operation is sometimes not…”
Get full text

Branched‐chain amino acids as pharmacological nutrients in chronic liver disease by Kawaguchi, Takumi, Izumi, Namiki, Charlton, Michael R., Sata, Michio

“…Branched‐chain amino acids (BCAAs) are a group of essential amino acids comprising valine, leucine, and isoleucine. A low ratio of plasma BCAAs to aromatic…”
Get full text

Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines) by Kokudo, Norihiro, Hasegawa, Kiyoshi, Akahane, Masaaki, Igaki, Hiroshi, Izumi, Namiki, Ichida, Takafumi, Uemoto, Shinji, Kaneko, Shuichi, Kawasaki, Seiji, Ku, Yonson, Kudo, Masatoshi, Kubo, Shoji, Takayama, Tadatoshi, Tateishi, Ryosuke, Fukuda, Takashi, Matsui, Osamu, Matsuyama, Yutaka, Murakami, Takamichi, Arii, Shigeki, Okazaki, Masatoshi, Makuuchi, Masatoshi

“…The 3rd version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of…”
Get full text

Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013) by Kudo, Masatoshi, Izumi, Namiki, Kokudo, Norihiro, Sakamoto, Michiie, Shiina, Shuichiro, Takayama, Tadatoshi, Tateishi, Ryosuke, Nakashima, Osamu, Murakami, Takamichi, Matsuyama, Yutaka, Takahashi, Arata, Miyata, Hiroaki, Kubo, Shoji

“…In the 22nd Nationwide Follow‐up Survey of Primary Liver Cancer in Japan, data from 21 155 newly registered patients and 43 041 previously registered follow‐up…”
Get full text

Efficacy of daclatasvir in hepatitis C virus by Izumi, Namiki

“…Daclatasvir is a novel NS5A inhibitor of hepatitis C virus (HCV). Daclatasvir combined with peginterferon α-2a and ribavirin in Japanese patients infected with…”
Get more information

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality by Tamaki, Nobuharu, Kimura, Takefumi, Wakabayashi, Shun‐Ichi, Umemura, Takeji, Kurosaki, Masayuki, Loomba, Rohit, Izumi, Namiki

“…Summary Background A multi‐society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic‐dysfunction associated…”
Get full text

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study by Kudo, Masatoshi, Ueshima, Kazuomi, Chan, Stephan, Minami, Tomohiro, Chishina, Hirokazu, Aoki, Tomoko, Takita, Masahiro, Hagiwara, Satoru, Minami, Yasunori, Ida, Hiroshi, Takenaka, Mamoru, Sakurai, Toshiharu, Watanabe, Tomohiro, Morita, Masahiro, Ogawa, Chikara, Wada, Yoshiyuki, Ikeda, Masafumi, Ishii, Hiroshi, Izumi, Namiki, Nishida, Naoshi

“…Although transcatheter arterial chemoembolization (TACE) is the standard of care for intermediate-stage hepatocellular carcinoma (HCC), this is a largely…”
Get full text

Report of the 19th follow-up survey of primary liver cancer in Japan by Kudo, Masatoshi, Izumi, Namiki, Ichida, Takafumi, Ku, Yonson, Kokudo, Norihiro, Sakamoto, Michiie, Takayama, Tadatoshi, Nakashima, Osamu, Matsui, Osamu, Matsuyama, Yutaka

“…The 19th Nationwide Follow‐up Survey of Primary Liver Cancer in Japan comprised 20 850 primary liver cancer patients newly registered at 482 medical…”
Get full text